Regulators in the U.S. and European Union handed AstraZeneca Plc
The agencies cleared Klygefa for generalized myasthenia gravis and approved the Imfinzi combination regimen for muscle-invasive bladder cancer.
FDA And EU Clear Klygefa For Generalized Myasthenia Gravis
Monday, the U.S. Food and Drug Administration and EU authorities approved Klygefa (gefurulimab) from Alexion, AstraZeneca Rare Disease, for adults with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG).
In the EU, regulators cleared the therapy as an add-on to standard treatment.
Klygefa acts as the first and only dual-binding nanobody C5 inhibitor, allowing patients to self-administer a once-weekly subcutaneous injection via an autoinjector.
Pivotal PREVAIL Phase 3 trial results backed both approvals, showing Klygefa improved Myasthenia Gravis Activities of Daily Living (MG-ADL) total scores at week 26 over placebo (-1.6 difference; p
